Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion.
Following successful coronary arterial thrombolysis, thrombogenic substrate persists, increasing the risk of recurrent thrombosis, reocclusion, and reinfarction. The preferred treatment in this setting has not been established. Although many patients receive mechanical revascularization, it is conceivable that repeat thrombolysis, primarily with tissue plasminogen activator, represents the most readily available and effective alternative.
Becker
R C
RC
Coronary Care Unit, University of Massachusetts Medical School, Worcester 01655.
D015906:Angioplasty, Balloon, Coronary; D003328:Coronary Thrombosis / Q000628:therapy*; D003663:Decision Trees; D006801:Humans; D007423:Intra-Aortic Balloon Pumping; D009203:Myocardial Infarction / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D013917:Thrombin / Q000037:antagonists & inhibitors; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014654:Vascular Patency
D010975:Platelet Aggregation Inhibitors; D013917:Thrombin; D010959:Tissue Plasminogen Activator